



Yes  No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

For the twelve months ended December 31, 2024, compared to twelve months ended December 31, 2023, the Company expects to report the following results of operations (dollars in thousands, other than per share numbers): Revenue for the year ended December 31, 2024, totaled approximately \$40 comprised of product sales of Nil and recognized service revenue of \$40, as compared to \$18 comprised of product sales of Nil and recognized service revenue of \$18 for the year ended December 31, 2023. Cost of sales for the year ended December 31, 2024 and 2023, was Nil. Gross profit for the year ended December 31, 2024, was approximately \$40 or 100.0% as compared to \$18 or 100.0% for the year ended December 31, 2023. Research and development expenses for the twelve months ended December 31, 2024, were approximately \$832, a decrease of approximately \$4,260 or 83.66%, from \$5,092 for the twelve months ended December 31, 2023. While the Company does not expect material changes to the aforementioned preliminary unaudited financial information, such preliminary financial information remains subject to change pending the completion of the Company's financial statements as of and for the year ended December 31, 2024.

#### Special Note About Forward-Looking Statements

This Notification of Late Filing on Form 12b-25 includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding that the Company expects to file its quarterly report on Form 10-K on or before the fifteenth calendar day following its prescribed due date, and the results of operations and the events that led to such results expected to be presented therein. These forward-looking statements are based upon information presently available to the Company and assumptions that it believes to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including the risks that additional resources and time may be needed to complete and file the Form 10-K, and that the Company's actual operating results may differ materially from these estimates upon completion of management's review of the financial statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this Form 12b-25.

3

---

#### BioSig Technologies, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date March 31, 2025 By /s/ Anthony Amato  
Name: Anthony Amato  
Title: Chief Executive Officer

4